Company news
Yabao Pharmaceutical Group Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
November 2, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Report for Q3 2026
October 27, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Use of Idle Self-owned Funds for Entrusted Wealth Management
October 27, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Stock Collateralized Repo Trading by Controlling Shareholder
October 27, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors
October 27, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Progress of Capital Reduction of a Controlled Subsidiary Following the Conversion of Capital Reserve into Registered Capital and Completion of Industrial and Commercial Registration Changes
October 20, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Progress of Capital Reduction of a Wholly-owned Subsidiary Following the Conversion of Capital Reserve into Registered Capital and Completion of Industrial and Commercial Registration Changes
October 19, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
October 8, 2026
Announcement on Share Pledge Repurchase Transaction by Controlling Shareholder
September 16, 2026
Announcement on Initial Repurchase of Shares through Call Auction
September 11, 2026
Announcement on Adjustment of Upper Limit of Share Repurchase Price Following Implementation of Dividend Distribution for the First Half of 2026
August 28, 2026
Announcement on Implementation of Dividend Distribution for the First Half of 2026
August 25, 2026
Announcement on the Progress of the Capital Increase in a Wholly-owned Subsidiary and the Completion of Industrial and Commercial Registration Changes
August 19, 2026
Announcement on Notifying Creditors
August 18, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 10, 2026
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase
August 4, 2026
Announcement on Share Repurchase Plan through Call Auction and the Repurchase Report
July 31, 2026
Announcement on Obtaining Drug Registration Certificate
July 2, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Scopolamine Transdermal Patch
June 25, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
June 16, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 12, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 8, 2026
Announcement on Election of Employee Representative Director for the 10th Session
June 4, 2026
Announcement on Resolutions of the 15th Meeting of the 9th Board of Directors
May 28, 2026
Announcement on the Wholly-owned Subsidiary Obtaining Drug Registration Certificate
May 22, 2026
Announcement on Attending 2026 Online Collective Reception Day for Investors of Listed Companies in Shanxi Jurisdiction
May 15, 2026
Announcement on Purchasing Liability Insurance for Directors and Senior Management Members
May 7, 2026
Announcement on Resolutions of the 13th Meeting of the 9th Board of Directors
April 24, 2026
Announcement on Obtaining Drug Registration Certificate
April 20, 2026
Announcement on Implementation of Dividend Distribution for Q3 2025
January 29, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
January 16, 2026
Announcement on Progress in the Sale of Subsidiary Equity and Completion of Industrial and Commercial Registration Change
December 22, 2025
Announcement on Profit Distribution Plan for Q3 2025
December 19, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of GLX002
December 17, 2025
Announcement on the Change of Signatory Certified Public Accountant and Quality Control Reviewer for the Audit Institution
December 12, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 21, 2025
Announcement on Implementation Result of Shares Repurchase and Share Changes
November 17, 2025
Announcement on Obtaining the Registration Certificate for Formula Foods for Special Medical Purposes
November 12, 2025
Announcement on Progress in Repurchasing Shares through Call Auction
November 3, 2025
Announcement on Progress in Repurchased Company Shares Reaching 1% and Repurchase
October 30, 2025
Report for Q3 2025
October 24, 2025
Announcement on Early Repurchase of Shares in Stock Pledge Repurchase Transactions by the Controlling Shareholder
September 29, 2025
Announcement on Holding Shareholders Engaging in Stock Pledge Repurchase Transactions
September 26, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of ZY-A002
September 23, 2025
Announcement on Termination of Clinical Trials for Research Projects and the Provision of Impairment Provisions
September 22, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of SY-005 with New Indications
August 25, 2025
2025 Semi-annual Report
August 15, 2025
Announcement on Signing the Technology Transfer Agreement for the New Traditional Chinese Medicine Project
August 5, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
July 10, 2025
Announcement on Transfer of Partnership Shares to Wholly-Owned Subsidiaries and Withdrawal from Partnership
July 4, 2025